Cassava Sciences Inc. (NASDAQ: SAVA) is a clinical-stage biotech company focused on developing Simufilam, an oral drug candidate for Alzheimer’s disease. Its platform is based on stabilizing a scaffolding protein (filamin A) thought to disrupt Alzheimer’s pathology. While the company faces scientific scrutiny and clinical trial volatility, it continues to advance large-scale Phase 3 studies. Cassava offers speculative exposure to high-stakes neurodegeneration treatment development with transformative, albeit controversial, upside potential.